ASCO 2019 | Melanoma retreatment with anti-PD1 therapy

Allison Betof Warner

Allison Betof Warner, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the long-term outcomes and responses to retreatment in melanoma patients who responded to PD-1 inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics